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Abstract
Information about the performance of diagnostic 
tests is typically presented in the form of measures 
of test accuracy such as sensitivity and specificity. 
These measures may be difficult to translate 
directly into decisions about patient treatment, 
for which information presented in the form of 
probabilities of disease after a positive or a negative 
test result may be more useful. These probabilities 
depend on the prevalence of the disease, which is 
likely to vary between populations. This article 
aims to clarify the relationship between pre-
test (prevalence) and post-test probabilities of 
disease, and presents two free, online interactive 
tools to illustrate this relationship. These tools 
allow probabilities of disease to be compared 
with decision thresholds above and below which 
different treatment decisions may be indicated. 
They are intended to help those involved in 
communicating information about diagnostic 
test performance and are likely to be of benefit 
when teaching these concepts. A substantive 
example is presented using C reactive protein 
as a diagnostic marker for bacterial infection in 
the older adult population. The tools may also 
be useful for manufacturers of clinical tests in 
planning product development, for authors of test 
evaluation studies to improve reporting and for 
users of test evaluations to facilitate interpretation 
and application of the results.
Background
Quantifying diagnostic accuracy is an important 
first step in assessing whether a new diagnostic 
device is suitable for implementation into clinical 
practice. Without initial evidence as to whether a 
device is able to improve diagnostic performance, 
it is difficult to justify larger studies to assess the 
impact on patient outcomes.
To many clinicians and researchers, statis-
tical measures of diagnostic accuracy (which we 
refer to in this paper as ‘technical accuracy’) may 
appear counterintuitive and may not adequately 
reflect how a test result should influence decisions 
about the treatment of the patient.1 This difficulty 
arises because many test accuracy study results are 
expressed in terms of sensitivity and specificity 
rather than measures of ‘clinical accuracy’; that 
is, the probability that the patient has the disease 
or condition under consideration after receiving a 
positive or a negative test result.2 3
There is also evidence that many clinicians find 
it difficult to extract usable probabilistic informa-
tion from diagnostic test accuracy results in the 
way that they are typically reported.4 5 However, 
there are conflicting opinions on the extent to 
which this depends on the type of information 
provided.6
The purpose of this article is twofold: to review 
the concepts of technical accuracy and clinical 
accuracy and highlight the measures of diag-
nostic performance that are particularly useful 
for statisticians, on the one hand, and patients 
and clinicians, on the other, and to demonstrate 
an interactive graphical interface to help medical 
educators and health professionals to teach, design 
and interpret the results of diagnostic accuracy 
studies.
Example
Serum C  reactive protein (CRP) is indicated as a 
marker of acute and chronic inflammation and 
bacterial infection and is widely used to assist in 
the diagnosis of these conditions.7 For illustration, 
we consider here the study of Liu et al,8 conducted 
in an older patient group (age >70 years). Defining 
elevated CRP levels as those exceeding 60 mg/L, 
the article reports the results in table  1 to show 
CRP test performance in relation to diagnosing 
bacterial infection, as assessed using a reference 
test based on clinical and microbiological criteria. 
The number of patients in each cell of the table is 
labelled as the number of true positive (TP), false 
positive (FP), false negative (FN) and true negative 
(TN) test results.
Assessing diagnostic performance
Often, the diagnostic performance of the test is 
expressed using as summary statistics the sensi-
tivity (proportion of infections correctly iden-
tified by the CRP test, TP/(TP+FN)=67/83=81%) 
and the specificity (proportion of non-infec-
tions correctly identified by the CRP test, TN/
(FP+TN)=143/149=96%).9 Although widely used, 
these statistics do not by themselves enable the 
user to judge the probability that a patient who 
receives a particular CRP test result has infection. 
This probability depends additionally on the prev-
alence, or pre-test probability, of infection—how 
common bacterial infections are in the patient 
group under consideration. In this case, the esti-
mated prevalence is 83/232=36%.
In the context of a single study, the rele-
vant post-test probabilities, or ‘predictive 
values’, can be calculated directly. The data 
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in table  1 enable us to estimate the positive predictive value 
(TP/(TP+FP)=67/73=92%) and the negative predictive value (TN/
(FN +TN)=143/159=90%).
Disease prevalences may vary considerably between patient 
groups and care settings, even those in which the same diagnostic 
test is used. This has a substantial impact on predictive values. 
For example, a Swiss prospective cohort study of 218 patients 
aged  >75 years found a lower prevalence of infection of 23% 
(50/218).10 However, provided the pre-test probability of infec-
tion is available, predictive values in the new population can be 
calculated on the assumption that the performance of the test 
remains the same. The prevalence of infection is likely to be a 
plausible estimate of the pre-test probability in the absence of 
other patient-specific information such as symptoms, signs or 
previous test results. 
Using the 23% prevalence from Stucker et al10 gives estimated 
probabilities of infection of 86% following a positive CRP test 
result and 5.6% following a negative test result. The Box provides 
details of the calculations, which use likelihood ratios11 estimated 
using the data from Liu et al.8 Both post-test probabilities are 
somewhat lower than those found in the setting described by Liu 
et al,8 which is a reflection of the reduced prevalence of infection 
in the Swiss population.
Interactive graphical presentation
To help visualise and interpret the results of probability calcula-
tions when assessing diagnostic tests, we have created two free 
interactive tools, titled ‘Test Accuracy’ (https:// micncltools. shin-
yapps. io/ TestAccuracy)12 and ‘Clinical Accuracy and Utility’ (http 
s:/ /mic nclt ools .shi nyap ps.io/ ClinicalAccu racyAndUtility).13 These 
were developed using the RStudio application ‘Shiny’.14
The first of these provides a clear interface for illustrating 
measures of diagnostic technical accuracy, that is, sensitivity 
and specificity. It does so by showing the natural frequencies 
of TP, TN, FP and FN that would result for a given prevalence 
and sample size. The screenshot in figure 1 displays in graphical 
form the same information that is shown in table 1 for the study 
of CRP and infection.
The second tool is designed to help users to interpret pre-test 
and post-test probabilities of disease in relation to clinical deci-
sion thresholds.15 Figure 2 shows results based on the calculation 
described above, showing the hypothetical performance of the 
CRP test (the ‘Index Test’) in a population with 23% prevalence. 
Additionally, predictive probabilities are shown across the full 
range of possible prevalences from 0% to 100% to show the user 
the relationship between these two parameters. CIs are depicted as 
the coloured bands around each curve to aid communication of 
uncertainties associated with test accuracy on the resulting clini-
cally relevant parameters.
The resulting predictive probabilities can easily be compared 
directly to rule-in or rule-out thresholds for clinical deci-
sion-making. In further options, these thresholds can be varied 
by the user, perhaps as a first step in performing a full decision 
curve analysis, in which decision-making is based on a trade-off 
between the consequences of FP and FN predictions.16
In practice, a range of decision thresholds has been proposed 
for CRP testing in different populations, as described in systematic 
reviews on the subject.7 17 For the purpose of illustration, suppose 
that a policy recommendation suggests that a particular treatment 
be initiated if the post-test probability of treatment exceeded 90%. 
Using the interactive tools, the user can change the available 
parameters to see the effect of improved or reduced performance 
of the test in a different setting, or the different prevalence of 
disease that might better reflect the characteristics of a new popu-
lation. Varying the prevalence of disease (figure  2) shows that, 
given the performance of the diagnostic test, this threshold would 
be exceeded for individuals who receive a positive test result only 
in populations for which the disease prevalence is above around 
30%. The threshold would therefore not be exceeded in the lower 
prevalence setting of the Swiss study described above.
These tools are intended to help those involved in commu-
nicating information about diagnostic test performance and are 
likely to be of benefit when teaching these concepts. They may 
also be useful for manufacturers of clinical tests in planning 
product development, for authors of test evaluation studies to 
improve reporting and for users of test evaluations to facilitate 
Table 1 Summary results table from a study of CRP and infection
Reference test result
Definite, probable or 
possible infection
No 
infection Total
CRP test 
result
Positive: elevated 
CRP (>60 mg/L)
TP=67 FP=6 73
Negative: non-
elevated CRP
(<60 mg/L)
FN=16 TN=143 159
Total 83 149 232
CRP, C reactive protein; FN, false negative; FP, false positive; TN, true 
negative; TP, true positive.
Box Calculation of post-test probabilities
 
Positive Diagnostic Likelihood Ratio
(
DLR+
)
=
TP/
(
TP+FN
)
FP/
(
FP+TN
) = 67/836/149 = 20.05 
 Post-test odds(+ve result) = DLR+ × Prevalence1−Prevalence = 20.05× 50/2181−50/218 = 5.97 
 Post-test probability (+ve result) = Post-test odds(+ve result)1+Post-test odds(+ve result) =
5.97
6.97 = 86% 
 Negative Diagnostic Likelihood Ratio (DLR−) = FN/(TP+FN)TN/(FP+TN) =
16/83
143/149 = 0.201 
 Post-test odds (−ve result) = DLR− × Prevalence1−Prevalence = 0.201× 50/2181−50/218 = 0.0598 
 Post-test probability (−ve result) = Post-test odds(−ve result)1+Post-test odds(−ve result) = 0.05981.0598 = 5.6% 
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interpretation and application of the results. Example scenarios 
include those in which predictive values are not provided directly, 
but can be inferred from sensitivity, specificity and prevalence 
information, and situations in which the prevalence of the condi-
tion varies. They could also be useful for authors of systematic 
reviews of diagnostic test accuracy studies to derive predictive 
values from sensitivity and specificity values. They have value 
in designing new studies, for which preliminary estimates of 
predictive values and their CIs are useful in helping to choose 
appropriate and ethical sample sizes. The tool quickly allows 
users to assess the impact of different sample size and prevalence 
assumptions on CIs, which can be compared directly against a 
decision-making threshold.
Conclusion
In summary, the clinical accuracy of diagnostic tests, as expressed 
by post-test probabilities, may be used to guide treatment deci-
sions. These probabilities may vary across different populations. 
We have created two free, interactive tools to help to visualise 
these concepts. Future work may include extending these tools 
to incorporate diagnostic results based on continuous measure-
ments.
Figure 1 Screenshot from the ‘Test Accuracy’ tool, giving a graphical representation of parameters relating to 
diagnostic performance. FN, false negative; NPV, negative predictive value; PPV, positive predictive value; TN, true 
negative; TP, true positive. 
Figure 2 Screenshot from the ‘Clinical Accuracy and Utility’ tool, showing the relationship between disease 
prevalence (or pre-test probability) and post-test probability. CRP, C reactive protein.
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